Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Qiagen ( (QGEN) ) has shared an update.
Qiagen has disclosed a voting rights announcement indicating that Bank of America Corporation, through various subsidiaries, holds a combined 3.11% capital and voting interest in the company. The position is composed of both real and potential holdings in ordinary shares and equity swaps, all held indirectly via entities such as BofA Securities, Merrill Lynch and related affiliates, reflecting a notable institutional stake in Qiagen’s shareholder base.
The notification, originally published by the Dutch Authority for the Financial Markets, shows that Qiagen is not responsible for the accuracy of the underlying data, which was taken from the regulator’s public register. While the filing does not signal an operational shift, it underlines continued interest from major U.S. financial institutions in Qiagen’s equity, a factor that can influence liquidity, governance dynamics and market perception of the stock.
The most recent analyst rating on (QGEN) stock is a Buy with a $49.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a Netherlands-based life sciences company specializing in sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its shares are listed on multiple European exchanges, including Frankfurt, as well as on the NYSE and Swiss markets, giving it broad international investor exposure.
Average Trading Volume: 2,017,406
Technical Sentiment Signal: Sell
Current Market Cap: $6.94B
For a thorough assessment of QGEN stock, go to TipRanks’ Stock Analysis page.